Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
Fast facts
- Category: Health
- Language: EN
- Published: 2026-04-27 07:01 UTC
- Sources: Stat News
Intellia Therapeutics' gene editing treatment lonvo-z showed promising results in a Phase 3 trial. It reduced swelling attacks in patients with a rare genetic disorder.
Why it matters
- This update can influence the Health agenda over the next 24-48 hours.
- It is based on 1 source, which helps cross-check key claims quickly.
- Watch follow-up statements and market/public response to assess real impact.